Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Marker for predicting therapeutic effect on hepatitis c, method for predicting therapeutic effect on hepatitis c, and prophylaxis or therapeutic agent for hepatitis c

A therapeutic effect and marker technology, applied in the fields of markers for predicting the therapeutic effect of hepatitis C, predicting the therapeutic effect of hepatitis C, and preventive or therapeutic agents for hepatitis C, can solve the problem of correct treatment effect. Problems such as prediction and inability to transfer SNP to achieve the effect of easy judgment and clear risk value

Inactive Publication Date: 2012-05-30
HEALTH SCI TECH TRANSFER CENT JAPAN HEALTH SCI FOUND +1
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] This is because the cure efficiency (significant efficiency) itself used as the criterion for SNP judgment is completely different between "IFN monotherapy" and "PEGylated IFN / RBV combination therapy", and therefore, the results derived for "IFN monotherapy" cannot be used Transfer of SNPs to SNPs for "PEGylated IFN / RBV Combination Therapy"
[0007] In addition, these conventional methods only study specific genes as candidates and do not fully verify the entire host genome, so there are still problems in accuracy
[0008] This is due to: in most cases, the therapeutic effect of a drug is related to multiple factors, and without comprehensive SNP validation for the entire genome, it cannot be called a correct prediction of the therapeutic effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Marker for predicting therapeutic effect on hepatitis c, method for predicting therapeutic effect on hepatitis c, and prophylaxis or therapeutic agent for hepatitis c
  • Marker for predicting therapeutic effect on hepatitis c, method for predicting therapeutic effect on hepatitis c, and prophylaxis or therapeutic agent for hepatitis c
  • Marker for predicting therapeutic effect on hepatitis c, method for predicting therapeutic effect on hepatitis c, and prophylaxis or therapeutic agent for hepatitis c

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0162] The preparation of the oligo(or poly)nucleotide can be carried out by a known method, but when the oligo(or poly)nucleotide is DNA, it can be obtained, for example, from blood cells such as lymphocytes or granulocytes in blood as a sample, by Salting out, PCI (phenol chloroform extraction) method, a method using a commercially available DNA extraction kit, etc., or other known methods are performed.

[0163] In addition, when the oligo (or poly) nucleotide is mRNA, the method of making the solution acidic to extract from the water layer in the PCI method, the method of using an Oligo-dT column, etc., or using a commercially available RNA extraction kit can be used. method, other known methods.

[0164] "Nucleic Acid Amplification"

[0165] When the amount of nucleic acid obtained from a sample is small, it can be amplified by a known method if necessary.

[0166] When the nucleic acid is DNA, PCR method or the like can be used.

[0167] When the nucleic acid is mRNA,...

Embodiment

[0196] [Prediction of therapeutic effect on hepatitis C using GWAS]

[0197] Using Affymetrix Genome-Wide Human SNP Array 6.0 (hereinafter referred to as SNP Array 6.0) equipped with more than 900,000 probes for SNP analysis, 154 people who received PEG-IFN / RBV combination therapy for chronic hepatitis C were tested SNP typing, divided into subgroups according to drug sensitivity (GWAS stage (GWAS Stage): 1st panel (1st panel): 82 people in the ineffective (NVR) group and 72 people in the effective (VR) group), and a genome-wide association study ( GWAS).

[0198] will choose a P value of 10 -5 Table 1 shows the results in the case of the level or lower.

[0199] In addition, the P value was calculated mainly by chi-square test.

[0200] In addition, the ineffective group refers to a sample in which the virus did not disappear even once during the treatment.

[0201] It can be seen from the results that, especially for the low-frequency alleles of SNPs (rs12980275 and rs80...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed are a marker for higher accuracy prediction of therapeutic effect, and a higher accuracy prediction method for the therapeutic effect on hepatitis C using the marker in a peg-IFN / RBV combination therapy. Specifically disclosed are a marker for predicting the therapeutic effect on hepatitis C that is characterized by being an oligonucleotide or a polynucleotide present in the human genome and by comprising one or more types selected from among the genetic polymorphism indicated below or those in a state of linkage disequilibrium (R2>0.8) with the same, and a prediction method for the therapeutic effect on hepatitis C using the marker. The genetic polymorphism present within a polynucleotide represented by rs12043519, rs1986953, rs13392065, rs16987149, rs16987155, rs2374341, rs2374342, rs7566701, rs12713624, rs10208788, rs10208883, rs9876122, rs2036081, rs13122167, rs4488950, rs13150115, rs7663113, rs1379606, rs913500, rs6458003, rs6906840, rs2224068, rs9390164, rs4512312, rs757844, rs4876271, rs7942675, rs17787293, rs917334, rs6489019, rs6489020, rs6489021, rs11610391, rs9528038, rs341554, rs2325219, rs1353348, rs2076954, rs12907066, rs8075713, rs4795794, rs955155, rs12972991, rs12980275, rs8105790, rs11881222, rs8103142, rs28416813, rs4803219, rs8099917, rs7248668, rs10853728, rs4803223, rs12980602, rs4803224, and sequence 59.

Description

technical field [0001] The present invention relates to a marker for predicting the therapeutic effect of hepatitis C that has been fully verified in the entire host genome, a method for predicting the therapeutic effect of hepatitis C with higher accuracy using the marker, and a probe used in the prediction. Needles, primers, or kits containing them, and prophylactic or therapeutic agents for hepatitis C, and the like. [0002] This application claims the priority of Japanese Patent Application No. 2009-192615 incorporated herein by reference. Background technique [0003] In the past, various studies have been conducted on methods for predicting the treatment effect of hepatitis C, but in most cases, the method of making judgments based on the "viral factor" infected by the patient is the mainstream. [0004] Specifically, the therapeutic effect of interferon (IFN) was predicted by variation in viral genotype or a specific region (core region or nonstructural region (NS5A...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/09A61K31/7088A61K38/00A61K48/00A61P1/16A61P31/14C12Q1/68
CPCC12Q2600/156C12Q1/6883C12N2770/24211A61K38/21C12Q2600/106C12N7/00A61K31/7088A61P1/16A61P31/14A61K2300/00
Inventor 田中靖人沟上雅史德永胜士
Owner HEALTH SCI TECH TRANSFER CENT JAPAN HEALTH SCI FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com